YARDLEY, Pa.--(BUSINESS WIRE)--Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the Company’s New Drug Application ...

YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that ...

YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

Xhance was evaluated in five trials enrolling >1,500 adults. Optinose announced that the Food and Drug Administration (FDA) has approved Xhance (fluticasone propionate) Nasal Spray for the treatment ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Xhance for the treatment of chronic rhinosinusitis without nasal polyps among patients aged 18 ...

Improvement was observed across a broad range of measures including multiple symptoms and both general and disease-specific quality of life YARDLEY, Pa., Sept. 29, 2020 /PRNewswire/ -- Optinose ...

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...

Xhance (fluticasone propionate) is a brand-name nasal spray that’s prescribed for chronic rhinosinusitis with or without nasal polyps in adults. Xhance has interactions with some other drugs, such as ...

Xhance (fluticasone propionate) is a prescription nasal spray. It’s used to treat nasal and sinus inflammation with or without nasal polyps in adults. This drug can interact with other medications, ...